Sanofi and Genzyme showcase MS drug data at AAN 2012

Sanofi and Genzyme are attending the American Academy of Neurology (AAN) 2012 annual meeting this week in order to demonstrate new clinical data for their innovative multiple sclerosis (MS) portfolio.

During the New Orleans conference, the companies are giving 12 data presentations – including six platform presentations – highlighting the latest developments from clinical studies of the drugs alemtuzumab and teriflunomide.

These include full data results from Care-MS II, a study comparing the efficacy of alemtuzumab to Rebif, as well as new findings from the teriflunomide clinical programme, which is among the largest of its kind for an MS drug.

Dr David Meeker, president and chief executive officer of Genzyme, said: "We are committed to becoming a long-term partner to the MS community with the goal of raising the expectation of what life with MS can be."

This comes after the European Medicines Agency accepted oral teriflunomide for regulatory review earlier this year.